Found 37 matching trials
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
PHASE1This is a Phase I clinical trial to assess the safety and dosimetry profile...
Location
Memorial Sloan Kettering Cancer Center
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
PHASE4The purpose of the study was to evaluate the effect of arginine/lysine solu...
Location
Istituto Europeo di Oncologia
Randomized Phase III of PRRT Versus Interferon
PHASE3The purpose of this study is to assess the benefit of 177Lu-DOTATATE versus...
Location
Jules Bordet Institute
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
PHASE2This pilot phase II trial studies how effective pembrolizumab and liver-dir...
Location
University of California, San Francisco
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
PHASE2This is a randomized phase II non-comparative study. Patients with gastroen...
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
PHASE1Background:
A neuroendocrine tumor is a rare type of tumor. It comes from ...
Location
National Institutes of Health Clinical Center
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
PHASE2Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is ofte...
Location
Cross Cancer Institute
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
PHASE2Peptide receptor radionuclide therapy (PRRT) with \[177Lu\]Lu-\[DOTA0,Tyr3\...
Location
Multiple Locations
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
N/AThis multicenter retrospective Italian study evaluates the efficacy and saf...
Location
Policlinico di Bari
Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
PHASE1The purpose of this study is to learn about the feasibility and safety of u...
Status
Active Not Recruiting
Location
Stanford Cancer Institute Palo Alto